Education
About Us
Working with TipRanks
Follow Us
Compass Pathways Plc (CMPS)
NASDAQ:CMPS
CMPS Stock Chart & Stats
$6.90
-$0.42(-9.17%)
At close: 4:00 PM EST
$6.90
-$0.42(-9.17%)
Day’s Range― - ―
52-Week Range$2.25 - $8.90
Previous CloseN/A
Volume477.34K
Average Volume (3M)3.56M
Market Cap
$662.41M
Enterprise Value$523.18M
Total Cash (Recent Filing)$185.94M
Total Debt (Recent Filing)$35.18M
Price to Earnings (P/E)―
Beta1.27
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding113,517,044
10 Day Avg. Volume8,220,464
30 Day Avg. Volume3,557,941
Financial Highlights & Ratios
PEG Ratio1.91
Price to Book (P/B)1.65
Price to Sales (P/S)0.00
P/FCF Ratio-2.14
Enterprise Value/Market Cap0.79
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.26
Forecast
1Y Price Target
$21.50Price Target Upside211.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-1.85
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyPhase 3 confirmatory trials of COMP360 met primary endpoints and demonstrated rapid, durable antidepressant effects, reinforcing the therapy's clinical credibility in treatment-resistant depression.
Commercial FeasibilityNew procedural billing codes and broader monitoring workforce options improve reimbursement mechanics and make specialty clinics more receptive to adopting COMP360.
Regulatory PathwayConsistent outcomes across independent pivotal studies and management plans to accelerate a rolling submission increase the likelihood of a smooth regulatory review for COMP360.
Bears Say
Control Arm ActivityA low-dose control arm exhibited clinical activity that reduced the observed treatment effect compared with earlier trials, which could complicate regulatory interpretation of efficacy.
Durability And Retreatment NeedsA single administration left a substantial portion of patients without a meaningful response, suggesting retreatment or additional dosing strategies may be required and could hinder real-world uptake.
Financial RiskHigh cash burn and a limited cash runway raise funding and dilution risk for ongoing development and commercialization of COMP360.
COMPASS Pathways News
CMPS FAQ
What was Compass Pathways Plc’s price range in the past 12 months?
Compass Pathways Plc lowest stock price was $2.25 and its highest was $8.90 in the past 12 months.
What is Compass Pathways Plc’s market cap?
Compass Pathways Plc’s market cap is $662.41M.
When is Compass Pathways Plc’s upcoming earnings report date?
Compass Pathways Plc’s upcoming earnings report date is May 07, 2026 which is in 65 days.
How were Compass Pathways Plc’s earnings last quarter?
Currently, no data Available
Is Compass Pathways Plc overvalued?
According to Wall Street analysts Compass Pathways Plc’s price is currently Undervalued.
Does Compass Pathways Plc pay dividends?
Compass Pathways Plc does not currently pay dividends.
What is Compass Pathways Plc’s EPS estimate?
Compass Pathways Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Compass Pathways Plc have?
Compass Pathways Plc has 113,517,044 shares outstanding.
What happened to Compass Pathways Plc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Compass Pathways Plc?
Currently, no hedge funds are holding shares in CMPS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
COMPASS Pathways Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.50 (211.59% Upside)
$21.50 (211.59% Upside)
Blogger Sentiment
Neutral
CMPS Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 56.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days >0.1%
Last 30 Days ▲ 8.6%
Last 30 Days ▲ 8.6%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
78.62%
12-Months-Change
Fundamentals
Return on Equity
-205.18%
Trailing 12-Months
Asset Growth
3.34%
Trailing 12-Months
Company Description
Compass Pathways Plc
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
CMPS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook with significant progress in clinical trials, regulatory interactions, and launch preparations. While there was a decrease in cash reserves, the company maintains a strong cash position with a runway into 2027.View all CMPS earnings summariesCMPS Stock 12 Month Forecast
Average Price Target
$21.50
▲(211.59% Upside)
Technical Analysis
Cross Country Healthcare
―
Oncology Institute
―
Talkspace
―
InnovAge Holding
―
Agilon Health
―
Ownership Overview
0.35% Insiders
0.89% Mutual Funds
9.68% Other Institutional Investors
85.36% Public Companies and Individual Investors